Agios Pharmaceuticals (AGIO) Net Margin (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 13 years of Net Margin data on file, last reported at 320.1% in Q2 2026.

• Quarterly Net Margin rose 73945.0% year-over-year to 320.1% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 510.95% (down 199831.0% YoY) and the FY2025 annual result came in at 764.01%, down 260994.0% from the prior year.
• Net Margin grew to 320.1% in Q2 2026, from 712.22% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 10574.69% in Q3 2024 to a low of 1551.83% in Q1 2023.
• A 4-year average of 212.83% and a median of 1120.35% in 2025 frame the typical range for Net Margin.
• Annual changes were most pronounced in 2024 — Net Margin surged 1180896 bps — and 2025, when it plunged 1137774 bps.
• Tracing AGIO's Net Margin over 4 years: stood at 1350.7% in 2023, then surged by 33 bps to 899.56% in 2024, then surged by 40 bps to 541.09% in 2025, then jumped by 41 bps to 320.1% in 2026.
• The last three Net Margin figures came in at 320.1% (Q2 2026), 712.22% (Q1 2026), and 541.09% (Q4 2025), per Business Quant data.